{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Objectives/Endpoints', 'Changed the third key secondary efficacy objective/endpoin from DOR to OS to', 'address the FDA request to remove the key secondary efficacy endpoint of DOR.', 'DOR is being replaced because it is not acceptable as a regulatory endpoint for', 'inferential purposes for an analysis that is based on a nonrandomized subgroup.', '(Modified sections: Synopsis and Sections 5.1.2, 5.1.3, 5.2.2.1, 5.2.3, and 13.5.2).', 'CCI', 'Revised the definition of time to response to \"the duration of time from', 'randomization to the first documented response ( PR) per IMWG response criteria\"', 'to address the FDA request to revise the starting point for time to response to \"time', 'from randomization\" (Modified section: Section 5.2.2.1).', 'IMWG Response Criteria', 'Updated the IMWG response criteria for myeloma to align with the most recent', 'IMWG criteria (Kumar, Lancet. 2016;17:328-346). The definition for MR was', 'changed from \"minor\" to \"minimal\" response to align with the IMWG Consensus', 'Criteria (Modified sections: Synopsis; Sections 5.0, 7.2, 11.3.1, and, Table 16).', 'Crossover', 'Clarified points 1 and 3 of the process that will be used to prevent premature', 'crossover. For point 1, Investigators will also assess PD on other symptoms and signs', 'of clinical progression that meet the IMWG criteria. For point 3, crossover will not be', 'permitted based purely on Investigator-assessed progression that does not meet any', 'IMWG criteria for PD and cannot be verified by IRC (eg, deteriorating performance', 'status). Also revised \"putative PD\" in point 5 to \"Investigator-assessed presumptive', 'PD to clarify the meaning of \"putative PD\" as requested by the FDA (Modified', 'section: Section 6.2).', 'Exclusion Criteria', 'Made minor wording changes to exclusion criteria 1 and 11, as follows, to align', 'standard text across protocols (Modified section: Section 7.3):', '- Criterion 1 changed from \"Has received selinexor or another XPO1 inhibitor', 'previously\" to \"Prior exposure to a SINE compound, including selinexor.\"', '- Criterion #11 changed from \"Intolerance, hypersensitivity, or contraindication to', 'glucocorticoids\" to \"Known intolerance, hypersensitivity, or contraindication to', 'glucocorticoids.\"', 'Confidential', 'Page 144', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Revised exclusion #12 to clarify that patients treated with an investigational', 'anticancer therapy within 2 weeks prior to C1D1 are specifically excluded from the', 'study (Modified section: Section 7.3).', 'Schedule of Assessments', 'Clarified that symptom-directed physical examinations will only be performed if', 'clinically indicated to address questions regarding invoicing symptom-directed', 'physical examinations that came up during preparation of the site contracts (Modified', 'sections: Tables 2 and 12).', 'Clarified that clinical plasmacytoma assessments are to be performed if clinically', 'indicated at MM Disease Assessment Visits and at Durability of Response and', 'Survival Follow-up Visits. Also corrected the window for detection of', 'plasmacytomas at baseline by physical examination/palpation from \"within 45 days\"', 'to', '\"within 28 days\" prior to C1D1 in footnote #21 of Table 2 (Modified sections:', 'Section 11.3.1.8 and Tables 2 and 12).', 'Clarified that a skeletal survey is required at the EoT Visit (Modified section:', 'Table 2).', 'Study Treatment Administration', 'Removed the requirement for dose escalation for patients in the SVd Arm who do not', 'achieve at least a PR within the first 2 cycles, are tolerating SVd well, and do not', 'have any AEs related to study treatment Grade >2 at the time of dose escalation. Dose', 'escalation is no longer be required for these patients, however, a dose escalation may', 'still be considered. This change was made to provide a greater margin of safety by', 'making a determination for escalation of the selinexor dose based on the medical', 'status of each individual patient. Also clarified that dose escalation is an option for all', 'selinexor-containing regimens (Modified sections: Synopsis, Section 10.2.4.1, and', 'Tables 8, 11, and 14; New section: Section 10.2.5).', 'Multiple Myeloma Disease Assessments', 'Added a requirement for baseline bone marrow aspirate at Screening for all because', 'the expectation in the field is that a baseline bone marrow aspirate is necessary to', 'obtain accurate 17p status prior to starting a new therapy, Also, clarified that a portion', 'of the bone marrow aspirate collected at Screening will be provided to the central', 'laboratory for karyotyping and fluorescence in situ hybridization (FISH) analysis to', 'confirm diagnosis and classify cytogenetic MM subtypes for R-ISS staging.', '(Modified sections: Section 11.3.1.9 and Table 2).', 'Removed turbidometry as an acceptable method for measuring quantitative Ig levels', 'because, unlike nephelometry, turbidometry cannot be used to assess response. Also', 'clarified that nephelometry may be used in place of SPEP for routine M-protein', 'measurement for patients with IgD myeloma in addition to patients with IgA', 'myeloma (Modified sections: Sections 11.3.1 and 11.3.1.3).', 'Confidential', 'Page 145', 'Version 4.0']\n\n###\n\n", "completion": "END"}